CERVIDIL^® (dinoprostone) is indicated for the initiation and/or continuation of cervical ripening in patients at or near term in whom there is a medical or obstetrical indication for the induction of labour.

Click here for additional safety information and for a link to the
product monograph discussing:

• Contraindications in patients who are hypersensitive to this drug or to any ingredient in the formulation; evidence of fetal distress where delivery is not imminent; placenta previa or unexplained vaginal bleeding; suspicion of marked cephalopelvic disproportion; when oxytocic drugs are contraindicated; when prolonged uterine contraction may be detrimental to fetal safety or uterine integrity; multipara with 6 or more previous term pregnancies; history of difficult labour and/or traumatic delivery; overdistension of uterus; fetal malpresentation; history of epilepsy with poorly controlled seizures; simultaneous use with other oxytocins; history of, or current pelvic inflammatory disease
• Serious Warnings and Precautions: For Hospital Use Only. CERVIDIL should be administered only by trained obstetrical personnel in a hospital setting with appropriate obstetrical care facilities
• Other relevant warnings and precautions regarding instruction on when to remove CERVIDIL; use in patients with ruptured membranes and history of previous uterine hypertonicity, glaucoma, or childhood asthma; use in women with complications during pregnancy and gestational age above 40 weeks; monitoring uterine activity, fetal status, and progression of dilation and effacement while CERVIDIL is in place; evaluation of cephalopelvic relationships prior to use; use in patients with severe renal disease and/or severe hepatic disease accompanied by metabolic aberrations.
• Conditions of clinical use, adverse reactions, drug interactions, and dosing instructions

The product monograph is also available through our medical department. Call us at 1-866-384-1314.